Hans Mueller

Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA.

TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs.

Founded in 2002, Othera Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing treatments for ophthalmic diseases. Othera is also engaged in the discovery of a novel set of orally available compounds to address severe medical conditions including inflammatory and oncology-related diseases.

Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Easton Capital Investment Group (Easton) is a Venture Capital firm which is founded in 2000 by John H. Friedman. The firm is headquartered in New York ,US.

Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA.

Amorcyte, Inc. provides cell therapy product development services. It focuses on developing cell therapeutics for cardiovascular disease. The company was founded by Andrew L. Pecora in 2004 and is headquartered in Allendale, NJ.

Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC.